TY - JOUR
T1 - Failure of Healthcare Provision for Attention-Deficit/Hyperactivity Disorder in the United Kingdom
T2 - A Consensus Statement
AU - Young, Susan
AU - Asherson, Philip
AU - Lloyd, Tony
AU - Absoud, Michael
AU - Arif, Muhammad
AU - Colley, William Andrew
AU - Cortese, Samuele
AU - Cubbin, Sally
AU - Doyle, Nancy
AU - Morua, Susan Dunn
AU - Ferreira-Lay, Philip
AU - Gudjonsson, Gisli
AU - Ivens, Valerie
AU - Jarvis, Christine
AU - Lewis, Alexandra
AU - Mason, Peter
AU - Newlove-Delgado, Tamsin
AU - Pitts, Mark
AU - Read, Helen
AU - van Rensburg, Kobus
AU - Zoritch, Bozhena
AU - Skirrow, Caroline
N1 - Funding Information:
We thank Takeda for sharing their Freedom of Information (FOI) data with us. We are grateful to the assistance of Lucy Warr, Catherine Coales, and Vicki Williams, who attended the consensus meeting and made notes during the breakout sessions. We are grateful to an informal external review and feedback on the first draft by a Consultant Psychiatrist working in CAMHS, who wished to remain anonymous. Funding. The meeting was jointly funded by the ADHD Foundation, the UK Adult ADHD Network (UKAAN), and the UK ADHD Partnership (UKAP). Other than reimbursement of travel expenses to attend the meeting, none of the authors received any financial compensation for attending the meeting or writing the manuscript, aside from CS who was remunerated for her time. PA was supported by NIHR Biomedical Research Center for Mental Health, NIHR/MRC (14/23/17) and NIHR senior investigator award (NF-SI-0616-10040). TN-D was funded by an NIHR Advanced Fellowship (NIHR300056). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.
Funding Information:
The meeting was jointly funded by the ADHD Foundation, the UK Adult ADHD Network (UKAAN), and the UK ADHD Partnership (UKAP). Other than reimbursement of travel expenses to attend the meeting, none of the authors received any financial compensation for attending the meeting or writing the manuscript, aside from CS who was remunerated for her time. PA was supported by NIHR Biomedical Research Center for Mental Health, NIHR/MRC (14/23/17) and NIHR senior investigator award (NF-SI-0616-10040). TN-D was funded by an NIHR Advanced Fellowship (NIHR300056). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.
Publisher Copyright:
© Copyright © 2021 Young, Asherson, Lloyd, Absoud, Arif, Colley, Cortese, Cubbin, Doyle, Morua, Ferreira-Lay, Gudjonsson, Ivens, Jarvis, Lewis, Mason, Newlove-Delgado, Pitts, Read, van Rensburg, Zoritch and Skirrow.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/3/19
Y1 - 2021/3/19
N2 - Background: Despite evidence-based national guidelines for ADHD in the United Kingdom (UK), ADHD is under-identified, under-diagnosed, and under-treated. Many seeking help for ADHD face prejudice, long waiting lists, and patchy or unavailable services, and are turning to service-user support groups and/or private healthcare for help. Methods: A group of UK experts representing clinical and healthcare providers from public and private healthcare, academia, ADHD patient groups, educational, and occupational specialists, met to discuss shortfalls in ADHD service provision in the UK. Discussions explored causes of under-diagnosis, examined biases operating across referral, diagnosis and treatment, together with recommendations for resolving these matters. Results: Cultural and structural barriers operate at all levels of the healthcare system, resulting in a de-prioritization of ADHD. Services for ADHD are insufficient in many regions, and problems with service provision have intensified as a result of the response to the COVID-19 pandemic. Research has established a range of adverse outcomes of untreated ADHD, and associated long-term personal, social, health and economic costs are high. The consensus group called for training of professionals who come into contact with people with ADHD, increased funding, commissioning and monitoring to improve service provision, and streamlined communication between health services to support better outcomes for people with ADHD. Conclusions: Evidence-based national clinical guidelines for ADHD are not being met. People with ADHD should have access to healthcare free from discrimination, and in line with their legal rights. UK Governments and clinical and regulatory bodies must act urgently on this important public health issue.
AB - Background: Despite evidence-based national guidelines for ADHD in the United Kingdom (UK), ADHD is under-identified, under-diagnosed, and under-treated. Many seeking help for ADHD face prejudice, long waiting lists, and patchy or unavailable services, and are turning to service-user support groups and/or private healthcare for help. Methods: A group of UK experts representing clinical and healthcare providers from public and private healthcare, academia, ADHD patient groups, educational, and occupational specialists, met to discuss shortfalls in ADHD service provision in the UK. Discussions explored causes of under-diagnosis, examined biases operating across referral, diagnosis and treatment, together with recommendations for resolving these matters. Results: Cultural and structural barriers operate at all levels of the healthcare system, resulting in a de-prioritization of ADHD. Services for ADHD are insufficient in many regions, and problems with service provision have intensified as a result of the response to the COVID-19 pandemic. Research has established a range of adverse outcomes of untreated ADHD, and associated long-term personal, social, health and economic costs are high. The consensus group called for training of professionals who come into contact with people with ADHD, increased funding, commissioning and monitoring to improve service provision, and streamlined communication between health services to support better outcomes for people with ADHD. Conclusions: Evidence-based national clinical guidelines for ADHD are not being met. People with ADHD should have access to healthcare free from discrimination, and in line with their legal rights. UK Governments and clinical and regulatory bodies must act urgently on this important public health issue.
KW - ADHD
KW - assessment
KW - healthcare commissioning
KW - service provision
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85103900749&partnerID=8YFLogxK
U2 - 10.3389/fpsyt.2021.649399
DO - 10.3389/fpsyt.2021.649399
M3 - Article
AN - SCOPUS:85103900749
SN - 1664-0640
VL - 12
JO - Frontiers in Psychiatry
JF - Frontiers in Psychiatry
M1 - 649399
ER -
